The online version of this article (doi:10.1186/s12879-017-2364-2) contains supplementary material, which is available to authorized users.
Diahn-Warng Perng and Yu Ru Kou contributed equally to this work.
While Candida pneumonia is life-threatening, biomarker measurements to early detect suspected Candida pneumonia are lacking. This study compared the diagnostic values of measuring levels of (1, 3)-β-D-glucan in endotracheal aspirate, bronchoalveolar lavage fluid, and serum to detect suspected Candida pneumonia in immunocompromised and critically ill patients.
This prospective, observational study enrolled immunocompromised, critically ill, and ventilated patients with suspected fungal pneumonia in mixed intensive care units from November 2010 to October 2011. Patients with D-glucan confounding factors or other fungal infection were excluded. Endotracheal aspirate, bronchoalveolar lavage fluid and serum were collected from each patient to perform a fungal smear, culture, and D-glucan assay.
After screening 166 patients, 31 patients completed the study and were categorized into non-Candida pneumonia/non-candidemia (n = 18), suspected Candida pneumonia (n = 9), and non-Candida pneumonia/candidemia groups (n = 4). D-glucan levels in endotracheal aspirate or bronchoalveolar lavage were highest in suspected Candida pneumonia, while the serum D-glucan level was highest in non-Candida pneumonia/candidemia. In all patients, the D-glucan value in endotracheal aspirate was positively correlated with that in bronchoalveolar lavage fluid. For the detection of suspected Candida pneumonia, the predictive performance (sensitivity/specificity/D-glucan cutoff [pg/ml]) of D-glucan in endotracheal aspirate and bronchoalveolar lavage fluid was 67%/82%/120 and 89%/86%/130, respectively, accounting for areas under the receiver operating characteristic curve of 0.833 and 0.939 (both P < 0.05), respectively. Measuring serum D-glucan was of no diagnostic value (area under curve =0.510, P = 0.931) for the detection of suspected Candida pneumonia in the absence of concurrent candidemia.
D-glucan levels in both endotracheal aspirate and bronchoalveolar lavage, but not in serum, provide good diagnostic values to detect suspected Candida pneumonia and to serve as potential biomarkers for early detection in this patient population.
Additional file 1: Supplementary Materials. (DOCX 24 kb)12879_2017_2364_MOESM1_ESM.docx
Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore). 1993;72:137–42. CrossRef
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46:1813–21. CrossRefPubMedPubMedCentral
el-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med. 1997;156:583–90. CrossRefPubMed
Albert M, Williamson D, Muscedere J, Lauzier F, Rotstein C, Kanji S, et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Med. 2014;40:1313–22. CrossRefPubMed
Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674–83. CrossRefPubMedPubMedCentral
Rose SR, Vallabhajosyula S, Velez MG, Fedorko DP, VanRaden MJ, Gea-Banacloche JC, et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. J Inf Secur. 2014;69:278–83.
Hoenigl M, Prattes J, Spiess B, Wagner J, Prueller F, Raggam RB, et al. Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52:2039–45. CrossRefPubMedPubMedCentral
Reischies FM, Prattes J, Pruller F, Eigl S, List A, Wolfler A, et al. Prognostic potential of 1,3-beta-d-glucan levels in bronchoalveolar lavage fluid samples. J Inf Secur. 2016;72:29–35.
Terraneo S, Ferrer M, Martin-Loeches I, Esperatti M, Di Pasquale M, Giunta V, et al. Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. Clin Microbiol Infect. 2016;22(94):e1–8.
Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-Glucan contamination of common antimicrobials. J Antimicrob Chemoth. 2016;71:913–5. CrossRef
Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-D-Glucan contamination of common antimicrobials-authors’ response. J Antimicrob Chemoth. 2016; 71:2997-2999.
Finkelman MA. Comment on: 1,3-beta-D-Glucan contamination of common antimicrobials. J Antimicrob Chemoth. 2016;71:2996–7. CrossRef
Hammarstrom H, Kondori N, Friman V, Wenneras C. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol. 2015;34:917–25. CrossRef
- Measuring (1,3)-β-D-glucan in tracheal aspirate, bronchoalveolar lavage fluid, and serum for detection of suspected Candida pneumonia in immunocompromised and critically ill patients: a prospective observational study
Vincent Yi-Fong Su
Yu Ru Kou
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II